Press Release
CytoMed Therapeutics Ltd — A Rising Star in Singapore’s Cancer Biotechnology Sector
In February 2026, The Wall Street Transcript published an exclusive interview with CytoMed Therapeutics Ltd (NASDAQ: GDTC) Chairman Choo Chee Kong. The interview covered the company’s technological approach, clinical trial progress, global strategic expansion — particularly in China and India — financing status, and deep insights into the global biotechnology industry.
1. Company Overview & Core Technology
Company Background
CytoMed is a clinical-stage biotech spin-off from ASTAR, Singapore’s national scientific research agency. The company focuses on developing affordable cancer therapy using patented allogeneic Gamma Delta T Cells derived from healthy donors.
Mission
The company aims to address the major limitations of existing cell therapies such as CAR-T, including high treatment costs and lengthy manufacturing timelines. By using blood from healthy donors to manufacture “off-the-shelf” immune cells, the company aims to reduce production costs and enable global distribution.
Technological Advantages
Safety
Gamma Delta T Cells have a lower risk of causing Graft-versus-Host Disease (GVHD), making them suitable for allogeneic transplantation.
Versatility
The cells express CARs (Chimeric Antigen Receptors) targeting NKG2D ligands, enabling recognition of multiple cancer types that express stress-related molecules, including Solid tumors & Hematological malignancies.
2. Clinical Trial Progress
Singapore ANGELICA Trial
Nature of the Trial
Ongoing first-in-human clinical trial targeting patients with:
Advanced solid tumors
Hematological malignancies
Progress
The trial comprised 12 patients in total, and treatment has been completed for half of the participants (6 patients).
Objective
To complete the Phase 1 clinical trial and evaluate before embarking on Phase 2 by next year 2027:
Safety
Efficacy of the CAR-modified version
Malaysia Clinical Trial
Strategy
CytoMed plans to launch a first-in-human clinical trial for the unmodified version of the therapy, which is expected to be significantly less expensive than the CAR-T version.
Collaboration
The company is collaborating with Universiti Malaya Hospital and is preparing to submit trial documentation to regulators and start by this year 2026.
3. Strategic Expansion & Acquisitions
Acquisition of TC BioPharm (UK)
Through this acquisition, CytoMed obtained feeder-free manufacturing technology, solving logistical challenges associated with cross-border transportation of specialized feeder cells and strengthening its cancer therapy platform.
Acquisition of Longevity Bank (Malaysia)
Background
In mid-2024, CytoMed acquired a Malaysian cord blood bank that had entered liquidation due to the impact of the pandemic. The bank had approximately 12,000 customers.
Strategic Purpose
The acquisition provides access to cord blood resources for the development of Natural Killer (NK) Cell therapies from pristine cord blood.
NK cells have potential applications in:
Anti-aging
Elimination of senescent cells
This acquisition also broadens the company’s therapeutic pipeline.
4. Global Market Strategy: Focus on China & India
China (Key Strategic Focus)
Policy Opportunity
CytoMed is closely monitoring China’s “Directive 818,” which allows hospitals conducting investigator-initiated trials (IITs) to charge patients, thereby helping subsidize biotechnology companies’ R&D and manufacturing costs.
Competitive Advantage
Compared with the capital-intensive “cash-burning” model commonly seen in Western biotech companies, the Chinese model is viewed as more sustainable.
China’s Government-backed biotech parks, Pragmatic regulatory policies & Strong venture capital ecosystem have made the country highly attractive for biotechnology development.
Market Potential
China has a massive cancer patient population and regulatory flexibility for compassionate-use style commercialization making it a critical strategic market for CytoMed.
India
As one of the world’s two largest population centres, India is also a major target market for the company.
United States
Although CytoMed collaborates with MD Anderson Cancer Center — where animal studies showed effectiveness against AML — the company currently does not prioritize the U.S. market due to the long time and extremely high cost of clinical trials.
5. Financial Position & Industry Perspectives
Financial Status
The company raised only USD 8 million during its 2023 IPO due to difficult biotech market conditions at the time.
However, management has maintained disciplined spending while seeking partners to co-develop its proprietary allogeneic cancer technologies.
View on the “Biotech Winter”
The Chairman believes the biotech industry is currently experiencing a “winter” caused by:
Excessively high valuations during the pandemic era
SPAC-related speculation
Significant investor losses
Tightening capital markets
The company also faces:
Heavy short-selling pressure
Interference from day traders
Strategic Pivot
To survive the difficult funding environment, CytoMed is shifting toward closer collaboration with hospitals to provide treatments for “no-option” patients.
The company benefits from low cost infrastructure in Southeast Asia and aims to:
Attract international medical tourists
Leverage Malaysia’s “Medical Tourism Year 2026”
Generate revenue while simultaneously collecting clinical data
6. Regulatory Advocacy
Compassionate Use
CytoMed advocates for regulators to adopt a more flexible approach for terminal patients who have exhausted all available treatment options, allowing access to new cell therapies.
East-West Differences
The Chairman noted that Eastern societies, particularly in Southeast Asia, generally have less aggressive litigation cultures compared with Western countries such as the United States.
This creates a more favourable environment for Compassionate Use programs, allowing terminal patients to try innovative therapies when conventional options have failed.
Conclusion
The interview highlights CytoMed’s unique “low-cost survival strategy” within the highly expensive biotechnology sector.
By leveraging:
Southeast Asia’s lower manufacturing and labour costs
Strategic hospital partnerships
China’s “Directive 818” policy framework
the company has identified a pragmatic commercialization pathway during the ongoing biotech capital winter.
CytoMed’s approach demonstrates not only technological ambition, but also strong strategic insight into the evolving global biotechnology landscape.
Media Contact:
Media Relations
CytoMed Therapeutics Ltd
Singapore
https://www.cytomed.sg/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Atlas Reserve Precious Metals Launches Transparent Gold IRA and Silver IRA Platform for Retirement Investors
Atlas Reserve Precious Metals LLC is a Wyoming-registered precious metals dealer focused on transparent pricing, physical delivery options, and secure depository storage for self-directed retirement investors. The company provides access to IRS-eligible bullion products, allocated storage solutions, and rollover support services for qualified retirement accounts, founded on the principle that physical gold and silver should be accessible, understandable, and fairly priced for Americans seeking to diversify their retirement portfolios with tangible assets.
Cheyenne, Wyoming, United States, 21st May 2026 – Atlas Reserve Precious Metals LLC, a Wyoming-registered precious metals dealer, has announced the official launch of its physical gold and silver bullion platform designed for self-directed Gold IRAs and Silver IRAs. The company provides access to IRS-eligible gold and silver coins and bars, supported by transparent spot-plus-premium pricing and allocated storage through U.S.-based depositories.
The platform was developed to provide a straightforward process for individuals seeking to include physical precious metals within self-directed retirement account structures. Atlas Reserve supports rollovers from eligible retirement accounts, including traditional IRAs, Roth IRAs, and 401(k) plans, with dedicated support throughout the account transfer process.
“Atlas Reserve gives American investors a simple, transparent way to allocate a portion of their 401(k) or IRA into physical precious metals”
said Diren Tercanoglu, Director and Founder of Atlas Reserve Precious Metals LLC.
“IRS-eligible gold and silver bullion at true low markups, combined with secure allocated storage and the flexibility of physical delivery – that is the foundation of what Atlas Reserve offers. The goal is to make real, physical assets accessible without the high fees or complexity that have historically made Gold IRAs difficult for everyday investors.”
Gold IRA and Silver IRA Platform Features
Atlas Reserve provides IRS-approved gold and silver coins and bars eligible for self-directed retirement accounts. Pricing follows a transparent spot-plus-premium structure with no undisclosed fees, offering investors clear visibility into premiums and transaction costs. The platform supports seamless rollover processing from 401(k)s, traditional IRAs, Roth IRAs, and other qualified plans. Storage is fully allocated and insured through leading U.S. depositories, with physical delivery available for investors who prefer direct possession.
401(k) to Gold IRA Rollover Guide
To support investors navigating the rollover process, Atlas Reserve has published a free educational resource covering eligibility requirements, IRS rules, custodian selection, and step-by-step rollover procedures. The guide is available at:
https://atlasreserve.global/ira/rollover-guide
About Atlas Reserve Precious Metals LLC
Atlas Reserve Precious Metals LLC is a Wyoming-registered precious metals dealer focused on transparent pricing, physical delivery options, and secure depository storage for self-directed retirement investors. The company provides access to IRS-eligible bullion products, allocated storage solutions, and rollover support services for qualified retirement accounts, founded on the principle that physical gold and silver should be accessible, understandable, and fairly priced for Americans seeking to diversify their retirement portfolios with tangible assets.
Website: https://atlasreserve.global
PR distributed by crmoonboy (crmoon): https://t.me/crmoon
Media Contact
Organization: Atlas Reserve Precious Metals LLC
Contact Person: Diren Tercanoglu
Website: https://atlasreserve.global/
Email:
admin@atlasreserve.global
Contact Number: +13076224606
City: Cheyenne
State: Wyoming
Country:United States
Release id:45242
The post Atlas Reserve Precious Metals Launches Transparent Gold IRA and Silver IRA Platform for Retirement Investors appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Niihara International Announces Launch of Corp. Website and SEC Qualification of Reg. A Offering
Niihara International, Inc. has launched a new corporate website and received SEC qualification of its Regulation A+ Tier 2 offering to support development and commercialization of therapies, including L‑glutamine for sickle cell disease and other unmet medical needs.
Irvine, California, United States, 21st May 2026– Niihara International, Inc. (“Niihara International” or the “Company”), today announced the launch of its new corporate website at www.niiharainternational.com and the qualification by the U.S. Securities and Exchange Commission (“SEC”) of the Company’s Regulation A+ Tier 2 offering of common stock. The Company is a pharmaceutical access company focused on expanding access to proven therapies for serious and underserved medical conditions.
The new website is designed to provide investors, patients, healthcare professionals, and other stakeholders with streamlined access to information about the Company’s business, product development plans, corporate governance and investor materials. The site features dedicated sections for corporate information, regulatory filings, and updates regarding Niihara International’s efforts to develop and commercialize innovative therapies, including its initial product candidate, a generic prescription-grade L‑glutamine oral powder for sickle cell disease.
Niihara International’s Regulation A+ Tier 2 offering has been qualified by the SEC pursuant to the Company’s Offering Circular, which is available on the SEC’s EDGAR system. Under the qualified offering, the Company is offering shares of its common stock on a “best efforts” basis, with the proceeds intended to fund product development, clinical, regulatory and commercialization activities, as well as general corporate purposes.
The Offering Circular and related information about the offering can be accessed by visiting the SEC’s website and searching for Niihara International, Inc. (CIK 0002062360) or via the Company’s own website via the link to its subscription portal provided below. Prospective investors are urged to carefully review the Offering Circular, including the section titled “Risk Factors,” and all other documents incorporated by reference before making any investment decision.
“This is an important milestone for Niihara International as we advance our strategy to develop and deliver therapies for patients with serious unmet medical needs,” said Founder and CEO Yutaka Niihara. “The launch of our new website and the qualification of our Regulation A+ Tier 2 offering provide a foundation to communicate more effectively with investors and partners as we seek to execute on our growth plans.”
The securities described in the Offering Circular are being offered pursuant to Regulation A under the Securities Act of 1933, as amended. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of securities will be made only by means of the Offering Circular and related subscription materials.
About Niihara International, Inc.
Niihara International, Inc., incorporated in California in 2023, is a development-stage biopharmaceutical company focused on the development, commercialization and distribution of innovative therapies. The Company is also focused on expanding access to proven therapies for serious and underserved medical conditions.
The Company’s initial product is a generic prescription-grade L‑glutamine oral powder designed to reduce acute complications associated with sickle cell disease in patients ages five years and older. For more information, please visit www.niiharainternational.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the Company’s business strategy, development plans, product candidates, potential markets, and the anticipated use of proceeds of the Regulation A+ Tier 2 offering. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described under “Risk Factors” in the Offering Circular and in other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release, and Niihara International, Inc. undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date hereof.
Offering Portal Administrator
Glass Box Law, Inc.
Offering Portal Website: https://glassboxlaw.com/portal/niihara-international-inc
Advancing Access to Essential Therapies for Patients with Unmet Medical Needs
Media Contact
Organization: Niihara International, Inc.
Contact Person: Maurice Bethea
Website: https://niiharainternational.com/
Email:
mbethea@niiharainternational.com
City: Rolling Hills Estates
State: California
Country:United States
Release id:45263
The post Niihara International Announces Launch of Corp. Website and SEC Qualification of Reg. A Offering appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Baiyunshan Hanfang Pharmaceutical Releases Technical Progress on Industrial High-Purity Lipid Raw Materials
This Enterprise Unveils Industrial High-Purity Lipid Raw Material Product Portfolio for Global Fine Chemical Clients
Guangzhou, Guangdong, China, 21st May 2026 – Guangzhou Hanfang Pharmaceutical Company Limited. (a subsidiary of Guangzhou Pharmaceutical Holdings Limited) today announced updates to its industrial lipid raw material product portfolio and global service upgrades. The company’s offerings include industrial high-purity egg yolk lecithin, medium-chain triglycerides, and soybean oil (general-purpose raw material), tailored to meet industrial production requirements across multiple regions. Adopting a comprehensive business model encompassing direct sales, distribution, custom processing, and technical support, the enterprise serves over 1,000 clients worldwide with a business network spanning more than 20 countries and regions, further expanding its global fine chemical supply chain footprint.
Core Product Portfolio and Technical Services
Guangzhou Baiyunshan Hanfang Pharmaceutical provides products and services tailored for industrial fine chemical enterprises and related industries:
- Industrial High-Purity Lipid Raw Materials: Supplies industrial high-purity egg yolk lecithin, medium-chain triglycerides, and soybean oil (general-purpose raw material), serving as core components for emulsifiers, cosolvents, and industrial energy additive raw materials, complying with process standards for industrial production scenarios.
- Customization and Technical Support: Delivers customized solutions for exclusive raw material formulation needs, including compliant adjustments to component ratios and performance parameters; the technical team provides end-to-end guidance on production process applications.
- Comprehensive Business Model: Covers direct sales, authorized distribution, custom processing, and technical services, meeting diverse needs from standard orders to customized projects.
Global Compliance and Quality Standards
The enterprise has established operational and quality systems aligned with international fine chemical supply chain norms. Its production base in Conghua, Guangzhou, adopts fully controlled end-to-end processes to ensure consistent product quality. Products are sold across Asia, Europe, and other regions, with efficient delivery enabled by mature logistics channels.
Supply and Service Information
Products are available globally through the direct sales team and authorized distributors. Orders are accepted from industrial fine chemical enterprises and related manufacturers, with standard production lead times provided. Custom processing services are available for premium clients, alongside formulation technical consultations. Clients may inquire via the official website or regional sales representatives.
“We focus on ensuring the stability of the fine chemical supply chain, with deep expertise in the lipid raw material sector,” said Chen Shiqi, Project Manager at Guangzhou Baiyunshan Hanfang Pharmaceutical. “We are committed to delivering stable, reliable products and technical support to meet the evolving needs of our global clients.”
Industry Background and Strategic Direction
Industry data indicates sustained growth in global demand for high-quality industrial lipid raw materials, driven primarily by the expansion of global fine chemical production capacity and the need for supply chain resilience. As a member enterprise of Guangzhou Pharmaceutical Holdings Limited, Baiyunshan Hanfang closely follows trends in the fine chemical supply chain industry, focusing on product stability and global technical services to support the growth of clients worldwide.
Future Plans
Guangzhou Baiyunshan Hanfang Pharmaceutical will continue to increase investment in production capacity and product R&D, with plans to expand its global distribution network, upgrade technical service systems for international clients, and prioritize meeting the diverse production needs of core markets.
About Guangzhou Hanfang Pharmaceutical Company Limited
Founded in 1998 and headquartered in Guangzhou, Guangzhou Hanfang Pharmaceutical Company Limited employs more than 330 people across production, R&D, quality control, and administration. The enterprise specializes in industrial fine chemical raw materials, lipid raw materials, and supporting technical services, with products sold in over 20 countries and regions. It holds multiple patents for lipid processing technologies, with its Conghua production base serving as the core production hub. The enterprise’s mission is “stable supply, technical collaboration, empowering the global fine chemical industry.”
For more information, please visit the official website: https://www.byshanhanfang.com/
Media Contact
Organization: Guangzhou Hanfang Pharmaceutical Company Limited
Contact Person: Ms. Chen Shiqi
Website: https://www.byshanhanfang.com/
Email: Send Email
Contact Number: +8613427652966
Address:No. 8 Wenquan Avenue, Wenquan Town, Conghua District, Guangzhou Guangdong Province, P.R. China
City: Guangzhou
State: Guangdong
Country:China
Release id:45292
The post Baiyunshan Hanfang Pharmaceutical Releases Technical Progress on Industrial High-Purity Lipid Raw Materials appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Atlas Reserve Precious Metals Launches Transparent Gold IRA and Silver IRA Platform for Retirement Investors
Niihara International Announces Launch of Corp. Website and SEC Qualification of Reg. A Offering
Baiyunshan Hanfang Pharmaceutical Releases Technical Progress on Industrial High-Purity Lipid Raw Materials
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release3 days ago
Community Rallies Around Tracey Archer Family Following Sudden Loss of Noah Thomas Archer
-
Press Release3 days ago
PortaProfits Releases Transparency Report: 30+ Partner Reviews Now Public
-
Press Release5 days ago
King VPN Offers 100+ Free VPN Locations for USA Users
-
Press Release5 days ago
Prime VPN: A Fast and Simple VPN App for UK Users with 70+ Free VPN locations
-
Press Release5 days ago
Secure VPN Announces 50+ Free VPN Locations for US Android Users
-
Press Release5 days ago
Readers Favorite announces the review of the Non-Fiction – Memoir book A Past That Lies Before Me by Steve Clark, PhD
-
Press Release5 days ago
Readers Favorite announces the review of the Non-Fiction – Memoir book A Past That Lies Before Me by Steve Clark, PhD
-
Press Release5 days ago
Aimelisz Introduces Glow Cleanser, a Minimalist Daily Cleanser Created for Sensitive and Dry Skin